Recruitment of patients to the Phase III study 14-431 to evaluate the efficacy and safety of ABT-494 in patients with Crohn's disease has been properly completed.
Study 14-431, sponsored by AbbVie: completion of recruitment
- Super User
- Trials
- Read Time: 1 min
- Hits: 0
Our partners
